Process for the purification of Montelukast

• US 20100029945A1
• Filed: 08/07/2007
• Published: 02/04/2010
• Est. Priority Date: 08/09/2006
• Status: Abandoned Application

• Current Assignee: Esteve Quimica SA (Corporation Quimico Farmaceutica Esteve SA)
• Original Assignee: Esteve Quimica SA (Corporation Quimico Farmaceutica Esteve SA)
• Inventors: Talavera Escasany, Pedro, Gasanz Guillén, Yolanda, Monsalvatje Llagostera, Montserrat
• Application Number:
  US12/376,773
• Publication Number:
  US 20100029945A1
• Time in Patent Office: Days
• US Class Current: 546/173
• CPC Class Codes: C07D 215/18 Halogen atoms or nitro radicals

Abstract

It relates to a process for the purification of Montelukast, or pharmaceutically salts thereof, or solvates thereof, including stereoisomers or mixture thereof which comprises carrying out a specific set of selective solvent extractions of Montelukast or its impurities in a mixture of an organic solvent and water at specific ranges of pH and temperature which depend on the type of impurities to remove. In particular, it comprises at least one wash of an aqueous phase containing crude Montelukast in salt form with an organic solvent, at a pH comprised between 12.0 and 13.5; and optionally one or more washes of the resulting aqueous phase with an organic solvent at a pH comprised between 8.5 and 10.0. Montelukast is recovered by acidification at a pH comprised between 4.5 and 8.0 and solvent extraction, and is isolated either as acid or in salt form.

Claims

1. A process for the purification of Montelukast, or a pharmaceutically acceptable salt thereof, or a solvate thereof, including any stereoisomer or mixture thereof which comprises carrying out a specific set of selective solvent extractions of Montelukast or its impurities, said set of solvent extractions comprising at least one wash of an aqueous phase containing crude Montelukast in salt form with an organic solvent, at a pH between 12.0 and 13.5 and at a temperature between about 10°

C. and about 5°

C. below the boiling point of the mixture.

2. The purification process according to claim 1, which comprises the following steps:

(a) carrying out at least one wash of an aqueous phase containing crude Montelukast in salt form with an organic solvent, at a pH between 12.0 and 13.5 and at a temperature between about 10°

C. and about 5°

C. below the boiling point of the mixture, and separating the aqueous phase containing the Montelukast in salt form;

(b) optionally, carrying out one or more washes of the aqueous phase of step (a) with an organic solvent at a pH between 8.5 and 10.0 and at a temperature between about 10°

C. and about 5°

C. below the boiling point of the mixture, and separating the aqueous phase containing the Montelukast in salt form;

(c) carrying out an extraction of the purified Montelukast from the aqueous phase of steps (a) or (b) with an organic solvent at a pH between 4.5 and 8.0 and at a temperature between about 10°

C. and about 5°

C. below the boiling point of the mixture, and separating the organic phase containing the Montelukast acid; and

(d) optionally, isolating the Montelukast from the organic phase of step (c) as acid or in salt form.

3. The purification process according to claim 1, wherein the organic solvent is selected from the group consisting of (C₂-C₈)-ether, (C₆-C₈)-aromatic hydrocarbon;

(C₁-C₃)-chlorine containing solvents, and mixtures thereof.

4. The purification process according to claim 3, wherein the solvent is selected from toluene, tert-butyl methyl ether, tetrahydrofuran, and mixtures thereof.

5. The purification process according to claim 1, wherein at least two washes are carried out at a pH equal to 12.0-13.5 and at a temperature between 20°

C. and 60°

C.

6. The purification process according to claim 2, wherein the washes of step (b) are carried out at a pH between 9.0 and 9.5, and at a temperature between 20°

C. and 60°

C.

7. The purification process according to claim 2, wherein the Montelukast is isolated from the organic phase of step (c) as acid, and optionally, is treated with a base to form a pharmaceutically acceptable salt of Montelukast.

8. The purification process according to claim 7, wherein the Montelukast acid is isolated by filtration.

9. The purification process according to claim 2, wherein the Montelukast is isolated from the organic phase of step (c) in salt form by adding a base and isolating from the reaction medium the corresponding pharmaceutically acceptable salt of Montelukast.

10. The purification process according to claim 9, wherein the salt of Montelukast is isolated by filtration.

11. The purification process according to claim 9, wherein the base is sodium hydroxide.

12. The purification process according to claim 1, further comprising a previous step where a compound of formula (II)

is reacted with an inorganic base in a mixture of an (C₁-C₆)-alcohol and water, to yield Montelukast crude.

13. The purification process according to claim 12, further comprising:

(a) optionally, separating the alcohol from the reaction medium;

(b) adding an organic solvent and water and separating the aqueous phase; and

(c) carrying out an extraction of the Montelukast in salt form from the organic phase with water;

to yield an aqueous phase containing Montelukast crude in salt form.

14. The purification process according to claim 1, wherein the aqueous phase containing crude Montelukast in salt form is obtained by adding an aqueous solution of a base to a mixture of Montelukast acid and an organic solvent.

15. The purification process according to claim 2, wherein the organic solvent is selected from the group consisting of (C₂-C₈)-ether, (C₆-C₈)-aromatic hydrocarbon;

(C₁-C₃)-chlorine containing solvents, and mixtures thereof.

16. The purification process according to claim 2, wherein at least are carried out two washes at a pH equal to 12.0-13.5 and at a temperature between 20°

C. and 60°

C.